A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2

J. C.L. Wang, A. Walle, A. Novogrodsky, Manikkam Suthanthiran, R. T. Silver, N. H. Bander, A. L. Rubin, K. H. Stenzel

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Forty patients with metastatic, recurrent, or unresectable renal cell carcinoma were entered into a study of the therapeutic efficacy of adoptive immunotherapy using periodate (IO4 -) and interleukin-2 (IL2)-activated autologous leukocytes and continuous infusion low-dose IL2. Patient survival was also examined. The first 15 consecutive patients were enrolled in protocol A without an IL2 priming phase and the following 25 patients were entered in protocol B where a 5-day priming phase was initiated before leukapheresis. A maintenance regimen consisted of either 3 x 106 units of recombinant interferon-alpha (rIFN-α), three times per week only or together with leukapheresis and infusion of IO4 -/IL2-activated cells and 2 days of continuous infusion IL2 per month. Thirty-four patients completed the protocol treatment. Four patients were removed from the study owing to rapid tumor progression and two patients died while receiving treatment. The clinical response rate was 22%: two patients had a complete response and five patients had a partial response. Among the 25 patients who had no clinical response, 11 patients had either a mixed response or stabilization. Neither response, response duration, nor site response correlated with the total dose of IL2 administered or the number of activated killer cells infused. Patients who received maintenance therapy had longer survival times than patients who did not receive such therapy. All toxicity and side effects associated with IL2 treatment were transient and resolved after discontinuation of the drug. Patients on maintenance therapy tolerated both rIFN-α and monthly infusions of activated killer cells and IL2 well. This study confirms the concept of adoptive immunotherapy as a new treatment approach for advanced renal cell carcinoma and suggests that maintenance therapy may prolong survival time.

Original languageEnglish
Pages (from-to)1885-1891
Number of pages7
JournalJournal of Clinical Oncology
Volume7
Issue number12
DOIs
Publication statusPublished - 1 Jan 1989
Externally publishedYes

Fingerprint

Adoptive Immunotherapy
Phase II Clinical Trials
Mitogens
Renal Cell Carcinoma
Interleukin-2
Leukocytes
Leukapheresis
Therapeutics
Interferon-alpha
Survival
Clinical Protocols

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2. / Wang, J. C.L.; Walle, A.; Novogrodsky, A.; Suthanthiran, Manikkam; Silver, R. T.; Bander, N. H.; Rubin, A. L.; Stenzel, K. H.

In: Journal of Clinical Oncology, Vol. 7, No. 12, 01.01.1989, p. 1885-1891.

Research output: Contribution to journalArticle

Wang, J. C.L. ; Walle, A. ; Novogrodsky, A. ; Suthanthiran, Manikkam ; Silver, R. T. ; Bander, N. H. ; Rubin, A. L. ; Stenzel, K. H. / A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 12. pp. 1885-1891.
@article{a0c13c69f63f440bb1d040873013d14f,
title = "A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2",
abstract = "Forty patients with metastatic, recurrent, or unresectable renal cell carcinoma were entered into a study of the therapeutic efficacy of adoptive immunotherapy using periodate (IO4 -) and interleukin-2 (IL2)-activated autologous leukocytes and continuous infusion low-dose IL2. Patient survival was also examined. The first 15 consecutive patients were enrolled in protocol A without an IL2 priming phase and the following 25 patients were entered in protocol B where a 5-day priming phase was initiated before leukapheresis. A maintenance regimen consisted of either 3 x 106 units of recombinant interferon-alpha (rIFN-α), three times per week only or together with leukapheresis and infusion of IO4 -/IL2-activated cells and 2 days of continuous infusion IL2 per month. Thirty-four patients completed the protocol treatment. Four patients were removed from the study owing to rapid tumor progression and two patients died while receiving treatment. The clinical response rate was 22{\%}: two patients had a complete response and five patients had a partial response. Among the 25 patients who had no clinical response, 11 patients had either a mixed response or stabilization. Neither response, response duration, nor site response correlated with the total dose of IL2 administered or the number of activated killer cells infused. Patients who received maintenance therapy had longer survival times than patients who did not receive such therapy. All toxicity and side effects associated with IL2 treatment were transient and resolved after discontinuation of the drug. Patients on maintenance therapy tolerated both rIFN-α and monthly infusions of activated killer cells and IL2 well. This study confirms the concept of adoptive immunotherapy as a new treatment approach for advanced renal cell carcinoma and suggests that maintenance therapy may prolong survival time.",
author = "Wang, {J. C.L.} and A. Walle and A. Novogrodsky and Manikkam Suthanthiran and Silver, {R. T.} and Bander, {N. H.} and Rubin, {A. L.} and Stenzel, {K. H.}",
year = "1989",
month = "1",
day = "1",
doi = "10.1200/JCO.1989.7.12.1885",
language = "English",
volume = "7",
pages = "1885--1891",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "12",

}

TY - JOUR

T1 - A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2

AU - Wang, J. C.L.

AU - Walle, A.

AU - Novogrodsky, A.

AU - Suthanthiran, Manikkam

AU - Silver, R. T.

AU - Bander, N. H.

AU - Rubin, A. L.

AU - Stenzel, K. H.

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Forty patients with metastatic, recurrent, or unresectable renal cell carcinoma were entered into a study of the therapeutic efficacy of adoptive immunotherapy using periodate (IO4 -) and interleukin-2 (IL2)-activated autologous leukocytes and continuous infusion low-dose IL2. Patient survival was also examined. The first 15 consecutive patients were enrolled in protocol A without an IL2 priming phase and the following 25 patients were entered in protocol B where a 5-day priming phase was initiated before leukapheresis. A maintenance regimen consisted of either 3 x 106 units of recombinant interferon-alpha (rIFN-α), three times per week only or together with leukapheresis and infusion of IO4 -/IL2-activated cells and 2 days of continuous infusion IL2 per month. Thirty-four patients completed the protocol treatment. Four patients were removed from the study owing to rapid tumor progression and two patients died while receiving treatment. The clinical response rate was 22%: two patients had a complete response and five patients had a partial response. Among the 25 patients who had no clinical response, 11 patients had either a mixed response or stabilization. Neither response, response duration, nor site response correlated with the total dose of IL2 administered or the number of activated killer cells infused. Patients who received maintenance therapy had longer survival times than patients who did not receive such therapy. All toxicity and side effects associated with IL2 treatment were transient and resolved after discontinuation of the drug. Patients on maintenance therapy tolerated both rIFN-α and monthly infusions of activated killer cells and IL2 well. This study confirms the concept of adoptive immunotherapy as a new treatment approach for advanced renal cell carcinoma and suggests that maintenance therapy may prolong survival time.

AB - Forty patients with metastatic, recurrent, or unresectable renal cell carcinoma were entered into a study of the therapeutic efficacy of adoptive immunotherapy using periodate (IO4 -) and interleukin-2 (IL2)-activated autologous leukocytes and continuous infusion low-dose IL2. Patient survival was also examined. The first 15 consecutive patients were enrolled in protocol A without an IL2 priming phase and the following 25 patients were entered in protocol B where a 5-day priming phase was initiated before leukapheresis. A maintenance regimen consisted of either 3 x 106 units of recombinant interferon-alpha (rIFN-α), three times per week only or together with leukapheresis and infusion of IO4 -/IL2-activated cells and 2 days of continuous infusion IL2 per month. Thirty-four patients completed the protocol treatment. Four patients were removed from the study owing to rapid tumor progression and two patients died while receiving treatment. The clinical response rate was 22%: two patients had a complete response and five patients had a partial response. Among the 25 patients who had no clinical response, 11 patients had either a mixed response or stabilization. Neither response, response duration, nor site response correlated with the total dose of IL2 administered or the number of activated killer cells infused. Patients who received maintenance therapy had longer survival times than patients who did not receive such therapy. All toxicity and side effects associated with IL2 treatment were transient and resolved after discontinuation of the drug. Patients on maintenance therapy tolerated both rIFN-α and monthly infusions of activated killer cells and IL2 well. This study confirms the concept of adoptive immunotherapy as a new treatment approach for advanced renal cell carcinoma and suggests that maintenance therapy may prolong survival time.

UR - http://www.scopus.com/inward/record.url?scp=0024815640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024815640&partnerID=8YFLogxK

U2 - 10.1200/JCO.1989.7.12.1885

DO - 10.1200/JCO.1989.7.12.1885

M3 - Article

C2 - 2555451

AN - SCOPUS:0024815640

VL - 7

SP - 1885

EP - 1891

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 12

ER -